Paul Hallen will oversee Nanoscope's global operations, including commercial readiness, supply chain, and cross-functional execution, as the company works toward regulatory approval and launch of MCO-010 (MOGENRY), a therapy developed to treat retinitis pigmentosa.
Paul Hallen will oversee Nanoscope's global operations, including commercial readiness, supply chain, and cross-functional execution, as the company works toward regulatory approval and launch of MCO-010 (MOGENRY), a therapy developed to treat retinitis pigmentosa.